Guaifenesin Dosing Recommendations
For adults and children over 2 years, guaifenesin should be dosed according to FDA-approved labeling: adults and children ≥12 years receive 200-400 mg (10-20 mL) every 4 hours, children 6 to <12 years receive 100-200 mg (5-10 mL) every 4 hours, and children 2 to <6 years receive 50-100 mg (2.5-5 mL) every 4 hours, with a maximum of 6 doses in 24 hours for all age groups 1.
Age-Based Dosing Algorithm
Adults and Adolescents (≥12 years)
- Standard dose: 200-400 mg (10-20 mL of oral solution) every 4 hours
- Maximum: 2400 mg/day (6 doses in 24 hours)
- Extended-release formulations: 600-1200 mg every 12 hours 1
Children 6 to <12 years
- Standard dose: 100-200 mg (5-10 mL of oral solution) every 4 hours
- Maximum: 1200 mg/day (6 doses in 24 hours) 1
Children 2 to <6 years
- Standard dose: 50-100 mg (2.5-5 mL of oral solution) every 4 hours
- Maximum: 600 mg/day (6 doses in 24 hours) 1
Children <2 years
- Consult a physician - not recommended for routine use without medical supervision 1
Formulation Details
The FDA-approved oral solution contains 100 mg guaifenesin per 5 mL (20 mg/mL concentration), available as a sugar-free, alcohol-free formulation 1. This allows for precise weight-based dosing across pediatric age groups.
Clinical Context and Evidence Quality
The dosing recommendations above come directly from FDA drug labeling 1, which represents the highest quality regulatory guidance. These doses are supported by pharmacokinetic studies demonstrating that age-based dosing achieves similar systemic exposure across pediatric age groups when adjusted appropriately 2.
Important caveat: While guaifenesin is widely used and FDA-approved as an expectorant, recent evidence questions its clinical efficacy. A 2025 clinical practice guideline notes that "there is no evidence regarding the effect, if any, on symptomatic relief of acute bacterial rhinosinusitis" 3, and a 2024 review concluded there is a "lack of significant benefits over placebo for upper respiratory disease" 4. Despite this, the medication has a well-established safety profile with minimal adverse effects 5, 6.
Practical Considerations
- Rounding tolerance: Guaifenesin can be rounded by up to 15% for ease of administration without significant clinical impact 7
- Dosing frequency: Immediate-release formulations require dosing every 4 hours to maintain therapeutic effect; extended-release formulations allow 12-hourly dosing 5
- Administration: Can be taken without regard to meals, though administration with food may improve gastrointestinal tolerability 5
- Safety: Well-tolerated in both adult and pediatric populations with primarily mild gastrointestinal side effects when they occur 6